Abstract
Schizophrenia is a complex psychiatric disorder characterized by a range of cognitive, emotional, and behavioral symptoms. Despite significant advancements in pharmacotherapy, challenges such as poor treatment adherence, limited efficacy, and adverse side effects remain prevalent. Drug delivery systems have emerged as promising approaches to overcome these challenges by improving drug targeting, bioavailability, and patient compliance. This review explores recent advancements in drug delivery systems tailored for the targeted treatment of schizophrenia. Various strategies, including nanoparticle-based formulations, lipid-based carriers, depot injections, and transdermal patches, are examined for their potential to enhance the delivery of antipsychotic medications to the brain while minimizing systemic side effects. Additionally, the review discusses the application of novel technologies, such as implantable devices and nanoscale drug carriers, in optimizing drug release kinetics and achieving sustained therapeutic effects. By highlighting recent developments and future prospects in drug delivery for schizophrenia treatment, this review aims to inform researchers, clinicians, and pharmaceutical developers about the evolving landscape of targeted therapy in mental health care.
Keywords:
Schizophrenia, Drug delivery systems, Nanoparticles
References
Schizophrenia spectrum and other psychotic disorders. In: Diagnostic and Statistical Manual of Mental Disorders DSM-5. 5th ed. Arlington, Va.: American Psychiatric Association; 2013.
2. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc’h C, Maziere B, Paillère-Martinot ML: In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001;21:207–214.
3. Boyer P, Lecrubier Y, Puech A J, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 1997;166: 68–72.
4. International 1. Sarker DK, Engineering of nanoemulsion for drug delivery, Current Drug Delivery, 2005;(2): 297-310.
5. Sole, I., Maestro A., Gonzalez C., Solans C. and Gutierrez J. M. Optimization of Nano-emulsion Preparation by Low-Energy Methods in an Ionic Surfactant System. Langmuir, 2006; vol. 22, 8326-8332.
6. Chhabra G, Chuttani K, Mishra AK, Pathak K. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind pharm. 2011;37(8): 907-16.
7. Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation International Journal of Pharmaceutics. 2004; 280:241–251.
8. Sheikh S, Faiyaz S, Sushma T, Farhan J, Roop K, Khar MA. Development and bioavailability assessment of ramipril nanoemulsion formulation. European Journal of Pharmaceutics and Biopharmaceutics. 2007; 66: 227–243.
9. Kentish, S.; Wooster, T.; Ashok kumar, M.; Balachandran, S.; Mawson, R.; Simons, L. The use of ultrasonics for nanoemulsion preparation. Innovat. Food Sci. Emerg. Tech. 2008; 9, 170-175.
10. Jafari, S.; He, Y.; Bhandari, B. Nano-emulsion production by sonication and micro-fluidization- a comparison. Int. J. Food Prop. 2006; 9, 475-485.
